Isatuximab

• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 Phase III 2 countries Intergroupe Francophone Du Myelome
• ISASOCUT-IFM2022-05-Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of… Recruiting
  2024-517099-39-00 Phase II 1 country Centre Hospitalier Universitaire De Poitiers
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting
  2023-507402-13-00 Phase III 2 countries Universitaetsklinikum Heidelberg AöR
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran… Recruiting
  2024-511437-35-00 Phase II/III 2 countries Assistance Publique Hopitaux De Paris
• A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or … Recruiting
  2023-507899-47-00 Phase II 1 country Goethe University Frankfurt
• Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Recruiting
  2022-500453-16-00 Phase II 1 country University Medical Centre Schleswig-Holstein
• Randomized prospective trial evaluating the efficacy of the antiCD38 monoclonal antibody isatuximab in the treatment of PCRA by major ABO mi… Recruiting
  2024-514351-14-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Recruiting
  2024-517215-67-00 Phase III 1 country Centre Hospitalier Universitaire De Poitiers
• Isatuximab in combination with novel agents in RRMM – Master protocol and control arm Recruiting
  2024-514988-25-00 Phase I/II 6 countries Sanofi-Aventis Recherche & Developpement
• Isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma Recruiting
  2024-514992-16-00 Phase I/II 6 countries Sanofi-Aventis Recherche & Developpement
• Isatuximab in combination with evorpacept and dexamethasone in RRMM Recruiting
  2024-514993-38-00 Phase I/II 6 countries Sanofi-Aventis Recherche & Developpement
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m… Ended
  2024-517020-18-00 Phase II 1 country Fundacion PETHEMA
• An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as ma… Ended
  2024-514527-42-00 Phase II 1 country Karolinska Institutet
• International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended
  2023-507180-19-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
• A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or … Ended
  2023-508870-27-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement
• SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM Ended
  2023-508869-32-00 Phase III 10 countries Sanofi-Aventis Recherche & Developpement
• A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy conta… Ended
  2024-516060-28-00 Phase II 1 country Hellenic Society Of Hematology
• Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended
  2024-517008-12-00 Phase III 1 country Fundacion PETHEMA
• Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuxima… Ended
  2024-512749-18-00 Phase II 2 countries Cancer Trials Ireland
• Isatuximab in combination with Lenalidomide-Dexamethasone compared to Lenalidomide-Dexamethasone in elderly patients (aged ≥70 years) with n… Ended
  2024-515581-13-00 Phase II 2 countries Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH
• A trial for relapsed Multiple Myeloma patients (Isatuximab-dexamethasone) Ended
  2024-513397-21-00 Phase II 1 country Emn Trial Office S.r.l. Impresa Sociale
• The REST (Replacing Steroids in the transplant ineligible) study. Ended
  2023-510194-34-00 Phase II 2 countries Oslo University Hospital HF
• Isatuximab in combination with belantamab mafodotin and dexamethasone in RRMM. Ended
  2024-514989-40-00 Phase I/II 3 countries Sanofi-Aventis Recherche & Developpement
• A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal… Ended
  2024-513422-38-00 Phase III 8 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.

Showing 1–24 of 36 trials